Imaging of Cognition, Learning, and Memory in Aging
NCT01297114 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 294
Last updated 2017-11-01
Summary
This investigation is designed to study how the brain functions when it is performing explicit memory tasks, and furthermore how the brain systems supporting performance on these tests change as a function of aging. Implicit memory tasks may be distinguished from explicit memory tests in that explicit memory characterizes the directed or intentional recollection of previously learned information or events. In contrast, implicit (or nonconscious) memory is expressed in the facilitation of performance on some task or judgment on a stimulus owing to a prior presentation of that stimulus, without any necessary conscious awareness of the prior presentation. The investigators propose to use functional Magnetic resonance Imaging (fMRI) to measure brain activity during the performance of carefully designed explicit memory tasks. Comparison of brain activity during the different test conditions will provide information about the brain areas that are involved in mediating specific aspects of performance. Both older and younger individuals will be tested in order to understand age related changes in the brain activity. In order to examine the interactions between participants' differential levels of amyloid burden and their performance on cognitive tasks and fMRI neural activation, the investigators also propose PET imaging of older participants.
Conditions
Interventions
- DRUG
-
Florbetaben
This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
Sponsors & Collaborators
-
National Institute on Aging (NIA)
collaborator NIH -
Yaakov Stern
lead OTHER
Principal Investigators
-
Yaakov Stern, PhD · Columbia University
Eligibility
- Min Age
- 20 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-03-31
- Primary Completion
- 2017-10-01
- Completion
- 2017-10-01
Countries
- United States
Study Locations
More Related Trials
-
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
NCT00855868 ·Status: COMPLETED ·Phase: PHASE2
-
Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
NCT01400425 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
NCT01565382 ·Status: COMPLETED ·Phase: PHASE3
-
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
NCT01044758 ·Status: COMPLETED ·Phase: PHASE2
-
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
NCT07012993 ·Status: RECRUITING ·Phase: PHASE2
-
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
NCT01222351 ·Status: COMPLETED ·Phase: NA
-
The Feasibility of Florbetapir Quantitation in Europe
NCT02107599 ·Status: COMPLETED ·Phase: PHASE4
-
Imaging Inflammation in Alzheimer's Disease With 11C-ER176
NCT03744312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People
NCT02669225 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
NCT01565291 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT07169630 ·Status: RECRUITING ·Phase: PHASE1
-
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
NCT00857415 ·Status: COMPLETED ·Phase: PHASE3
-
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
NCT01202994 ·Status: COMPLETED ·Phase: PHASE2
-
Implications for Management of PET Amyloid Classification Technology
NCT02778971 ·Status: COMPLETED
-
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
NCT01020838 ·Status: COMPLETED ·Phase: PHASE3
-
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT04305210 ·Status: UNKNOWN ·Phase: PHASE2
-
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
NCT02016560 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
NCT00702143 ·Status: COMPLETED ·Phase: PHASE2
-
Brain Imaging and Mental Disorders of Aging Intervention
NCT00267163 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
NCT01518374 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
NCT00456417 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
NCT00750282 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Language and Memory in Patients With Alzheimer's Disease
NCT00593372 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
NCT01703702 ·Status: COMPLETED ·Phase: PHASE4
-
Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study
NCT03057938 ·Status: WITHDRAWN ·Phase: PHASE2